Diaceutics PLC
LSE:DXRX
Diaceutics PLC
LSE:DXRX
Price:
166
GBX
Market Closed
Market Cap:
£141m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Diaceutics PLC
LSE:DXRX
|
UK |
|
H
|
Hefei Chipmore Technology Co Ltd
SSE:688352
|
CN |
|
S
|
SKF India Ltd
BSE:500472
|
IN |
|
V
|
Vrain Solution Inc
TSE:135A
|
JP |
|
Intergis Co Ltd
KRX:129260
|
KR |
|
EpiCentre Holdings Ltd
SGX:5MQ
|
SG |
|
I
|
Ikab Securities and Investment Ltd
BSE:514238
|
IN |
|
Immuno-Biological Laboratories Co Ltd
TSE:4570
|
JP |
|
N
|
Novo Resources Corp
SWB:1NO
|
CA |
|
P
|
PXP Energy Corp
XPHS:PXP
|
PH |
Cash Flow Statement
Cash Flow Statement
Diaceutics PLC
Diaceutics PLC
Currency: GBP
| Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||
| Net Income |
(1)
|
(1)
|
0
|
(0)
|
1
|
(0)
|
(2)
|
(4)
|
(2)
|
(2)
|
|
| Depreciation & Amortization |
1
|
1
|
2
|
2
|
3
|
4
|
5
|
5
|
5
|
5
|
|
| Stock-Based Compensation |
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
1
|
1
|
|
| Other Non-Cash Items |
0
|
0
|
0
|
1
|
0
|
(0)
|
(0)
|
(0)
|
1
|
1
|
|
| Cash Taxes Paid |
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
1
|
1
|
1
|
|
| Cash Interest Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
|
| Change in Working Capital |
0
|
(0)
|
(2)
|
(0)
|
1
|
(1)
|
(1)
|
0
|
(3)
|
(4)
|
|
| Cash from Operating Activities |
0
N/A
|
0
-5%
|
1
+136%
|
3
+346%
|
5
+100%
|
3
-50%
|
1
-48%
|
2
+35%
|
1
-63%
|
0
-84%
|
|
| Investing Cash Flow | |||||||||||
| Capital Expenditures |
(6)
|
(6)
|
(6)
|
(5)
|
(5)
|
(5)
|
(5)
|
(3)
|
(5)
|
(6)
|
|
| Other Items |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
|
| Cash from Investing Activities |
(6)
N/A
|
(6)
+4%
|
(6)
+8%
|
(5)
+7%
|
(5)
+9%
|
(5)
-7%
|
(4)
+17%
|
(3)
+38%
|
(4)
-54%
|
(6)
-38%
|
|
| Financing Cash Flow | |||||||||||
| Net Issuance of Common Stock |
20
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
|
| Net Issuance of Debt |
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Other |
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
|
| Cash from Financing Activities |
20
N/A
|
(0)
N/A
|
(0)
-134 900%
|
(0)
-17%
|
(0)
+39%
|
(0)
-50%
|
(0)
+17%
|
(0)
+74%
|
(0)
-5%
|
(0)
-278%
|
|
| Change in Cash | |||||||||||
| Effect of Foreign Exchange Rates |
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(1)
|
|
| Net Change in Cash |
14
N/A
|
(6)
N/A
|
(6)
+7%
|
(3)
+40%
|
0
N/A
|
(3)
N/A
|
(3)
-27%
|
(1)
+64%
|
(4)
-247%
|
(6)
-62%
|
|
| Free Cash Flow | |||||||||||
| Free Cash Flow |
(6)
N/A
|
(6)
+4%
|
(5)
+14%
|
(3)
+47%
|
0
N/A
|
(3)
N/A
|
(4)
-22%
|
(2)
+55%
|
(4)
-150%
|
(6)
-48%
|
|
Switch to:
Switch to:
See Also
Discover More
